Bringing medicines to Parkinson's patients around the world
Posted by
17-Jun-2015
At UCB, we harness the latest scientific knowledge in order to improve the lives of patients – wherever they may be. We mean it when we say we are Inspired by Patients. Driven by Science.
Science is a truly global endeavour that reaches beyond borders and patients with unmet medical need are to be found in every country of the world. That is why it is important to us that the medicines we develop and produce reach as many people as possible.
However, not all patient populations respond in the same way to medicines. Sometimes, the effect of a medication could be a little better or worse in, for example, an African population compared to a Caucasian population. For this reason, national regulators in some countries ask pharmaceutical companies to conduct studies examining how their population responds to medicines.
With this in mind, UCB has presented results from a clinical study we conducted in China. The data was shared at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego (June 14-18).
The research looked at the efficacy and safety of one of UCB's medicines in treating 247 patients in China with early-stage Parkinson's disease. Patients show improved activities of daily living and motor function compared with placebo.
Conducted by the Peking Union Medical College Hospital, Beijing, as well as by 23 other medical centers in China, it is an important step on the road to bringing our medicines to Chinese patients. The therapy in question is already available in 46 countries worldwide, including the US, the European Union and Japan.
The research presented at the international conference in San Diego will form part of a regulatory application in China later this year.
Reference
Zhang Z et al. Efficacy and safety of rotigotine transdermal patch in Chinese patients with early-stage Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego, USA, June 14-18, 2015.
Science is a truly global endeavour that reaches beyond borders and patients with unmet medical need are to be found in every country of the world. That is why it is important to us that the medicines we develop and produce reach as many people as possible.
However, not all patient populations respond in the same way to medicines. Sometimes, the effect of a medication could be a little better or worse in, for example, an African population compared to a Caucasian population. For this reason, national regulators in some countries ask pharmaceutical companies to conduct studies examining how their population responds to medicines.
With this in mind, UCB has presented results from a clinical study we conducted in China. The data was shared at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego (June 14-18).
The research looked at the efficacy and safety of one of UCB's medicines in treating 247 patients in China with early-stage Parkinson's disease. Patients show improved activities of daily living and motor function compared with placebo.
Conducted by the Peking Union Medical College Hospital, Beijing, as well as by 23 other medical centers in China, it is an important step on the road to bringing our medicines to Chinese patients. The therapy in question is already available in 46 countries worldwide, including the US, the European Union and Japan.
The research presented at the international conference in San Diego will form part of a regulatory application in China later this year.
Reference
Zhang Z et al. Efficacy and safety of rotigotine transdermal patch in Chinese patients with early-stage Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego, USA, June 14-18, 2015.
Leave a Comment